Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Benign Prostatic Hyperplasia-Pipeline Review, H1 2015

Benign Prostatic Hyperplasia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Benign Prostatic Hyperplasia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Benign Prostatic Hyperplasia-Pipeline Review, H1 2015', provides an overview of the Benign Prostatic Hyperplasia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Benign Prostatic Hyperplasia Overview 10

Therapeutics Development 11

Pipeline Products for Benign Prostatic Hyperplasia-Overview 11

Pipeline Products for Benign Prostatic Hyperplasia-Comparative Analysis 12

Benign Prostatic Hyperplasia-Therapeutics under Development by Companies 13

Benign Prostatic Hyperplasia-Therapeutics under Investigation by Universities/Institutes 15

Benign Prostatic Hyperplasia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Benign Prostatic Hyperplasia-Products under Development by Companies 20

Benign Prostatic Hyperplasia-Products under Investigation by Universities/Institutes 23

Benign Prostatic Hyperplasia-Companies Involved in Therapeutics Development 24

AbbVie Inc. 24

Addex Therapeutics Ltd 25

AmVac AG 26

AndroScience Corporation 27

Aphios Corporation 28

Ausio Pharmaceuticals, LLC 29

Biolab Sanus Farmaceutica Ltda. 30

Chong Kun Dang Pharmaceutical Corp. 31

Corium International, Inc. 32

Curadis GmbH 33

Euroscreen S.A. 34

Hanmi Pharmaceuticals, Co. Ltd. 35

IntelGenx Corp. 36

Jeil Pharmaceutical Co., Ltd. 37

KAEL-GemVax Co., Ltd. 38

Kaken Pharmaceutical Co., Ltd. 39

Meiji Seika Pharma Co., Ltd. 40

Mezzion Pharma Co. Ltd. 41

Neurocentrx Pharma Ltd. 42

Nymox Pharmaceutical Corporation 43

Ono Pharmaceutical Co., Ltd. 44

Quest PharmaTech Inc. 45

SK Chemicals Co., Ltd. 46

SOM Innovation Biotech SL 47

Sophiris Bio, Inc. 48

Yungjin Pharm Ind. Co., Ltd. 49

Benign Prostatic Hyperplasia-Therapeutics Assessment 50

Assessment by Monotherapy Products 50

Assessment by Combination Products 51

Assessment by Target 52

Assessment by Mechanism of Action 54

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

(tamsulosin hydrochloride + dutasteride)-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ADX-68692-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

AMV-110-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

ASC-JM.X2-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

AUS-131-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

BL-214-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CKD-902-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

CR-1493-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Drugs for Burning Sensation-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

ESN-364-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

HCP-1303-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

HIP-1402-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

INT-0031-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

JLP-1207-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

L-1AD3-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

MCS-2-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

NCE-403-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

NX-1207-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

ONO-8430506-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

S-40542-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

SL-052-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

SOM-2391-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

SOM-2393-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Sperol-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

talaporfin sodium-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

tamsulosin hydrochloride-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

tamsulosin hydrochloride CR-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

tertomotide-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

topsalysin-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

udenafil-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

YBH-1603-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

YOB-1604-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Benign Prostatic Hyperplasia-Recent Pipeline Updates 103

Benign Prostatic Hyperplasia-Dormant Projects 119

Benign Prostatic Hyperplasia-Discontinued Products 123

Benign Prostatic Hyperplasia-Product Development Milestones 125

Featured News & Press Releases 125

Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 125

Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 125

Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 126

Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 126

Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 127

Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 127

Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 128

Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 129

May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 129

Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH 130

Appendix 132

Methodology 132

Coverage 132

Secondary Research 132

Primary Research 132

Expert Panel Validation 132

Contact Us 132

Disclaimer 133

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2015 11

Number of Products under Development for Benign Prostatic Hyperplasia-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Comparative Analysis by Unknown Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Development by Companies, H1 2015 (Contd..2) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Benign Prostatic Hyperplasia-Pipeline by AbbVie Inc., H1 2015 24

Benign Prostatic Hyperplasia-Pipeline by Addex Therapeutics Ltd, H1 2015 25

Benign Prostatic Hyperplasia-Pipeline by AmVac AG, H1 2015 26

Benign Prostatic Hyperplasia-Pipeline by AndroScience Corporation, H1 2015 27

Benign Prostatic Hyperplasia-Pipeline by Aphios Corporation, H1 2015 28

Benign Prostatic Hyperplasia-Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 29

Benign Prostatic Hyperplasia-Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 30

Benign Prostatic Hyperplasia-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 31

Benign Prostatic Hyperplasia-Pipeline by Corium International, Inc., H1 2015 32

Benign Prostatic Hyperplasia-Pipeline by Curadis GmbH, H1 2015 33

Benign Prostatic Hyperplasia-Pipeline by Euroscreen S.A., H1 2015 34

Benign Prostatic Hyperplasia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 35

Benign Prostatic Hyperplasia-Pipeline by IntelGenx Corp., H1 2015 36

Benign Prostatic Hyperplasia-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 37

Benign Prostatic Hyperplasia-Pipeline by KAEL-GemVax Co., Ltd., H1 2015 38

Benign Prostatic Hyperplasia-Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 39

Benign Prostatic Hyperplasia-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 40

Benign Prostatic Hyperplasia-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 41

Benign Prostatic Hyperplasia-Pipeline by Neurocentrx Pharma Ltd., H1 2015 42

Benign Prostatic Hyperplasia-Pipeline by Nymox Pharmaceutical Corporation, H1 2015 43

Benign Prostatic Hyperplasia-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 44

Benign Prostatic Hyperplasia-Pipeline by Quest PharmaTech Inc., H1 2015 45

Benign Prostatic Hyperplasia-Pipeline by SK Chemicals Co., Ltd., H1 2015 46

Benign Prostatic Hyperplasia-Pipeline by SOM Innovation Biotech SL, H1 2015 47

Benign Prostatic Hyperplasia-Pipeline by Sophiris Bio, Inc., H1 2015 48

Benign Prostatic Hyperplasia-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 49

Assessment by Monotherapy Products, H1 2015 50

Assessment by Combination Products, H1 2015 51

Number of Products by Stage and Target, H1 2015 53

Number of Products by Stage and Mechanism of Action, H1 2015 55

Number of Products by Stage and Route of Administration, H1 2015 57

Number of Products by Stage and Molecule Type, H1 2015 59

Benign Prostatic Hyperplasia Therapeutics-Recent Pipeline Updates, H1 2015 103

Benign Prostatic Hyperplasia-Dormant Projects, H1 2015 119

Benign Prostatic Hyperplasia-Dormant Projects (Contd..1), H1 2015 120

Benign Prostatic Hyperplasia-Dormant Projects (Contd..2), H1 2015 121

Benign Prostatic Hyperplasia-Dormant Projects (Contd..3), H1 2015 122

Benign Prostatic Hyperplasia-Discontinued Products, H1 2015 123

Benign Prostatic Hyperplasia-Discontinued Products (Contd..1), H1 2015 124

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2015 11

Number of Products under Development for Benign Prostatic Hyperplasia-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 50

Number of Products by Top 10 Targets, H1 2015 52

Number of Products by Stage and Top 10 Targets, H1 2015 52

Number of Products by Top 10 Mechanism of Actions, H1 2015 54

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 54

Number of Products by Top 10 Routes of Administration, H1 2015 56

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 57

Number of Products by Top 10 Molecule Types, H1 2015 58

Number of Products by Stage and Top 10 Molecule Types, H1 2015 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Addex Therapeutics Ltd

AmVac AG

AndroScience Corporation

Aphios Corporation

Ausio Pharmaceuticals, LLC

Biolab Sanus Farmaceutica Ltda.

Chong Kun Dang Pharmaceutical Corp.

Corium International, Inc.

Curadis GmbH

Euroscreen S.A.

Hanmi Pharmaceuticals, Co. Ltd.

IntelGenx Corp.

Jeil Pharmaceutical Co., Ltd.

KAEL-GemVax Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Meiji Seika Pharma Co., Ltd.

Mezzion Pharma Co. Ltd.

Neurocentrx Pharma Ltd.

Nymox Pharmaceutical Corporation

Ono Pharmaceutical Co., Ltd.

Quest PharmaTech Inc.

SK Chemicals Co., Ltd.

SOM Innovation Biotech SL

Sophiris Bio, Inc.

Yungjin Pharm Ind. Co., Ltd.

Benign Prostatic Hyperplasia Therapeutic Products under Development, Key Players in Benign Prostatic Hyperplasia Therapeutics, Benign Prostatic Hyperplasia Pipeline Overview, Benign Prostatic Hyperplasia Pipeline, Benign Prostatic Hyperplasia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com